This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Why You Might Swap Your Merck for Johnson & Johnson

In addition, "Second-quarter 2012 net earnings included after-tax special items of approximately $2.2 billion as shown in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items, net earnings for the current quarter were $4.3 billion and diluted earnings per share were $1.48, representing increases of 17.7% and 13.8%, respectively, as compared to the same period in 2012."

Now let's look at an apples-to-apples comparison between JNJ and MRK. The following one-year chart includes the share prices and the trailing twelve month (TTM) revenue growth numbers. It won't be hard to tell who the clear winner is in both categories.

JNJ Chart JNJ data by YCharts

Consumer products account for 21% of JNJ's total sales, and this segment has continued to perform well since Johnson & Johnson acquired Pfizer's consumer division back in 2007.

My enthusiasm for JNJ also stems from its shareholder-friendly history. It has increased its dividend each year for a half a century, which is partly why it's been one of Warren Buffett's favorites.

Former Chairman and CEO William Weldon owns over 307,000 shares of JNJ as of Feb. 2013. The current JNJ chairman and CEO, Alex Gorsky, owns nearly 70,000 shares.

Many favor JNJ's strength and the diversification of its global businesses. It maintains a strong balance sheet, produces earnings surprises and has rock-solid management execution.

At the Friday close of $87.16, the stock is down almost 8% from recent highs so we have a chance to buy the best on sale. Agreeing with Link and Cramer that a target price of $94 is reasonable, I also favor buying any dips.

You might also consider a trailing stop loss alert system like TradeStops to track the performance of your JNJ shares, protect your profits and to limit your chances of unacceptable losses.

I've tested it and used it for years and I favor it as a stealth way to set trailing stop losses without the chance of being "picked off" by vigilant market-makers. It's also an effective way to keep our emotions out of the investing process.

Wishing you good fortune and best returns!

At the time of publication the author is long JNJ and PFE.

This article was written by an independent contributor, separate from TheStreet's regular news coverage.
Marc Courtenay is the founder and owner of Advanced Investor Technologies, LLC, as well as the publisher and editor of

Courtenay holds a Master's of Science degree in Psychology from California Polytechnic State University, and is a former senior vice-president of Investments for two major brokerage firms. He's been a fiercely independent investment "investigator" and a consulting contributor to the investment publishing world for over 30 years. In addition to his role as an investment publisher and analyst, he serves as a marketing consultant to the investment media industries.

In his role as a financial editor, he specializes in unique investment strategies, overlooked stock investments, energy and resource companies, precious metals, emerging growth companies, the prudent use of option strategies,real estate related opportunities,wealth preservation, money-saving offers, risk management, tax issues, as well as "the psychology of investing". Because of his training and background in Clinical Counseling and Psychology, he enjoys writing about investor behavior, the ¿herd mentality, how to turn investment mistakes into investment breakthroughs and the stock market's behavioral trends and patterns.

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
JNJ $111.62 -0.76%
MRK $54.72 -1.80%
AAPL $93.18 -1.70%
GOOG $690.10 -0.13%
FB $116.53 -0.17%


Chart of I:DJI
DOW 17,691.26 -139.50 -0.78%
S&P 500 2,055.14 -20.67 -1.00%
NASDAQ 4,752.6650 -52.6260 -1.10%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs